Table 1 Overall characteristics of prostate cancer survivors by survival outcome, 1975–2019
From: Trends in suicide mortality among prostate cancer survivors in the United States, 1975–2019
Alive (N = 2,308,923) | Suicide cause (N = 7108) | Non-suicide cause (N = 1,233,941) | Total (N = 3,549,972) | |
|---|---|---|---|---|
Age (year) | ||||
Mean (SD) | 56.8 (14.4) | 62.3 (14.4) | 67.8 (12.9) | 64.0 (14.4) |
Median [Min, Max] | 57.5 [17.5, 85.0] | 67.5 [17.5, 85.0] | 67.5 [17.5, 85.0] | 67.5 [17.5, 85.0] |
< 55 | 502,596(40.6%) | 1855 (26.1%) | 352,367 (15.2%) | 856,818 (24.1%) |
55–64 | 344,125 (27.9%) | 1693 (23.8%) | 480,103 (20.8%) | 825,921 (23.3%) |
65–74 | 272,246 (22.1%) | 2206 (31.0%) | 694,199 (30.1%) | 968,651 (27.3%) |
75–84 | 96,995 (7.9%) | 1146 (16.1%) | 567,945 (24.6%) | 666,086 (18.8%) |
≥ 85 | 17,979 (1.5%) | 208 (2.9%) | 214,309 (9.3%) | 232,496 (6.5%) |
Race | ||||
White | 1,014,269 (82.2%) | 6623 (93.2%) | 1,970,953 (85.4%) | 2,991,845 (84.3%) |
Black | 93,658 (7.6%) | 158 (2.2%) | 163,889 (7.1%) | 257,705 (7.3%) |
Othersa | 126,014 (10.2%) | 327 (4.6%) | 174,081 (7.5%) | 300,422 (8.5%) |
Year of diagnosis | ||||
1975–1984 | 30,538 (2.5%) | 1536 (21.6%) | 504,167 (21.8%) | 536,241 (15.1%) |
1985–1994 | 87,146 (7.1%) | 2022 (28.4%) | 620,420 (26.9%) | 709,588 (20.0%) |
1995–2004 | 238,814 (19.4%) | 1786 (25.1%) | 592,082 (25.6%) | 832,682 (23.5%) |
2005–2019 | 877,443 (71.1%) | 1764 (24.8%) | 592,254 (25.7%) | 1,471,461 (41.5%) |
Marital status | ||||
Married | 371,430 (30.1%) | 2578 (36.3%) | 919,607 (39.8%) | 1,293,615 (36.4%) |
Single | 750,665 (60.8%) | 3985 (56.1%) | 1,279,031 (55.4%) | 2,033,681 (57.3%) |
SDW | 111,846 (9.1%) | 545 (7.7%) | 110,285 (4.8%) | 222,676 (6.3%) |
Household income | ||||
< $35,000 | 4028 (0.3%) | 25 (0.4%) | 6018 (0.3%) | 10,071 (0.3%) |
$35,000-$54,999 | 125,150 (10.1%) | 698 (9.8%) | 198,708 (8.6%) | 324,556 (9.1%) |
$55,000-$74,999 | 489,347 (39.7%) | 1963 (27.6%) | 611,602 (26.5%) | 1,102,912 (31.1%) |
$75,000+ | 551,940 (44.7%) | 1883 (26.5%) | 691,175 (29.9%) | 1,244,998 (35.1%) |
Unknown | 63,476 (5.1%) | 2539 (35.7%) | 801,420 (34.7%) | 867,435 (24.4%) |
Tumor stage | ||||
Localized/regional | 763,578 (61.9%) | 4113 (57.9%) | 1,087,200 (47.1%) | 1,854,891 (52.3%) |
Distant | 48,290 (3.9%) | 760 (10.7%) | 525,128 (22.7%) | 574,178 (16.2%) |
Unknown | 422,073 (34.2%) | 2235 (31.4%) | 696,595 (30.2%) | 1,120,903 (31.6%) |
Surgery record | ||||
Undergo surgery | 312,875 (25.4%) | 4356 (61.3%) | 1,178,289 (51.0%) | 2,103,711 (59.3%) |
Without surgery | 312,875 (25.4%) | 2752 (38.7%) | 1,130,634 (49.0%) | 1,446,261 (40.7%) |
Radiotherapy record | ||||
Receiving radiotherapy | 395,453 (32.0%) | 1997 (28.1%) | 659,614 (28.6%) | 1,057,064 (29.8%) |
Without radiotherapy | 838,488 (68.0%) | 5111 (71.9%) | 1,649,309 (71.4%) | 2,492,908 (70.2%) |
Survival month | ||||
Mean (SD) | 130 (110) | 77.3 (83.9) | 64.7 (85.9) | 87.3 (99.9) |
Median | 103 | 48.0 | 25.0 | 48.0 |